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Summary
Recent technological advances in sequencing have flooded the field of cancer research with knowledge about
somatic mutations for many different cancer types. Most cancer genomics studies focus on mutations that alter
the amino acid sequence, ignoring the potential impact of synonymous mutations. However, accumulating
experimental evidence has demonstrated clear consequences for gene function, leading to a widespread
recognition of the functional role of synonymous mutations and their causal connection to various diseases.
Here, we review the evidence supporting the direct impact of synonymous mutations on gene function via gene
splicing; mRNA stability, folding, and translation; protein folding; and miRNA-based regulation of expression.
These results highlight the functional contribution of synonymous mutations to oncogenesis and the need to
further investigate their detection and prioritization for experimental assessment.
The identification of cancer-causing mutations and the
corresponding functionally impacted processes repre-
sents the main goal of cancer genomics. The inception
of large collaborative efforts such as The Cancer Genome
Atlas (TCGA) and the International Cancer Genome
Consortium (ICGC) has led to the discovery of numerous
causal or driver mutations in many cancer types. Never-
theless, tumors continue to be found in the absence of
conspicuous mutational events, such as nucleotide sub-
stitutions, translocations, or copy number variants involv-
ing genes with well-established tumorigenic connections.
The lack of clear driver events in some cancers motivates
the search for somatically acquired events that are more
rare or have less obvious functional consequences but
mechanistically converge on genes and pathways
involved in oncogenesis and tumor progression.
Always in focus: non-synonymous
mutations
The identification of the molecular basis of human
cancers (Bishop, 1987; Poiesz et al., 1980; Stehelin et al.,
1976; Varmus, 1984) has fueled the search for cancer-
related genes and corresponding mutational events with
functional oncogenic relevance. Although identification of
such genes in the past has relied on low-throughput
techniques, such as linkage mapping (Bronner et al.,
1994; Fishel et al., 1993; Leach et al., 1993; Peltomaki
et al., 1993), the genomic era has enabled the search for
somatically acquired mutations in cancers, and conse-
quently for cancer-related genes, by directly comparing
the sequence of cancer genomes with a reference
genome sequence (Futreal et al., 2001). Genes linked to
oncogenesis can be functionally grouped into two broad
categories, oncogenes and tumor suppressors (Vogel-
stein et al., 2013). Oncogenes initiate and accelerate the
tumorigenic process in the context of gain-of-function
mutations (i.e., those leading to increased expression),
whereas tumor suppressor genes confer growth advan-
tage to cells upon acquiring loss-of-function mutations.
Recent advances in sequencing technology have
enabled the discovery of an increasingly large number
of functionally important somatic mutations in many
cancer types (Berger et al., 2012; Davies et al., 2002;
Greenman et al., 2007; Hodis et al., 2012; Kandoth et al.,
2013; Krauthammer et al., 2012; Nikolaev et al., 2012;
Parsons et al., 2008; Pleasance et al., 2010; Samuels
et al., 2004; Stark et al., 2012; Wei et al., 2011). In turn,
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these mutations have allowed the discovery of novel
cancer-related genes, such as BRAF (Davies et al., 2002),
PIK3CA (Samuels et al., 2004), and IDH1 (Parsons et al.,
2008). They have also revealed the dual functional nature
of some genes, such as NOTCH1, which acts as an
oncogene in T-cell acute lymphoblastic leukemia (Weng
et al., 2004), and as a tumor suppressor gene in
squamous cell carcinoma (Agrawal et al., 2011; Stransky
et al., 2011). Additionally, these studies have reinforced
the non-random nature of mutational patterns in cancer-
related genes. Specifically, driver mutations in oncogenes
tend to be recurrent (i.e., found in multiple samples) and
to occur in hot spots that correspond to specific protein
functional domains. One of the best-known examples of
oncogenic hot spots is the codon 600 of BRAF (Davies
et al., 2002), where most frequent mutations change the
encoded amino acid from valine to glutamic acid (V600E).
These mutations are common in many cancer types,
including melanoma and colorectal and ovarian cancers.
Other well-known recurrent mutations include NRAS
mutations, such as Q61R and Q61K, which are frequently
found in melanoma (Curtin et al., 2005; Lee et al., 2011;
Platz et al., 2008); KRAS G12D, which is the most
common KRAS mutation in colon and pancreatic cancers
(Kim et al., 2011; Neumann et al., 2009); and IDH1
R132H, together with other mutations of residue R132,
in gliomas (Yan et al., 2009). In the case of tumor
suppressor genes, inactivating mutations occur through-
out the gene without preference for mutational hot spots.
Such mutations can affect tumor suppressor genes in
several ways, including premature truncation by non-
sense mutations, alteration of function through the
accumulation of missense mutations, and removal or
truncation of important functional regions by insertions or
deletions (Kamb et al., 1994; Lopez et al., 2012; Wei
et al., 2011). It is important to note that all these
mutations have an obvious impact on the protein product
through either amino acid replacement or protein trunca-
tion. This observation also extends to the mutations
considered in the ‘20/20’ test designed to classify genes
into oncogenes or tumor suppressors (Vogelstein et al.,
2013). It follows that most cancer studies continue to
focus on finding frequently recurring missense, non-
sense, and insertion/deletion mutations with obvious
protein impact; more rare occurrences of other types of
driver mutations are overlooked as a consequence.
A case for a role of synonymous mutations
in cancer?
One particular class of mutations has been consistently
overlooked in cancer studies, namely synonymous muta-
tions or substitutions. They consist of single nucleotide
changes in gene coding sequences that do not affect the
amino acid encoded by the affected codon. For this
reason, they are usually referred to as either synonymous
or silent mutations. Many cancer studies completely
ignore synonymous mutations (e.g., Agrawal et al., 2012;
Sankin et al., 2014), whereas others use them to build
neutral background models of mutation clustering for the
detection of activating mutations (Tamborero et al.,
2013). Using an individual as a point of reference, such
mutations can be defined as somatic, or de novo,
mutations when acquired during one’s lifetime, or germ-
line mutations when inherited from either parent. In the
latter case, they represent a subset of single nucleotide
polymorphisms (SNPs) segregating in the population, and
are sometimes referred to as sSNPs.
Apart for their mute effect on the encoded protein, the
disregard for such DNA modifications may be rooted in
the assumption that synonymous sites are not subject to
selection (Kimura, 1977; King and Jukes, 1969). Accumu-
lating evidence of selection acting on synonymous
codons has challenged the assumption of neutrality for
synonymous sites (Iida and Akashi, 2000; Shields et al.,
1988), although it has been argued that in mammals it is
more difficult to distinguish patterns of neutral evolution
from signatures of selective pressure due to traits with
minor phenotypic effects (Duret, 2002). Various studies
have also shown that the rate of evolution at synonymous
sites is lower than the rate of evolution observed at
cognate pseudogenes or intergenic sequences (Busta-
mante et al., 2002; Hellmann et al., 2003). Specific
examples have provided molecular mechanisms, such
as gene splicing, that could explain this increased evolu-
tionary pressure (Hurst and Pal, 2001; Orban and Olah,
2001; Pagani et al., 2005; Parmley et al., 2006). Some
studies estimate that up to 40% of synonymous muta-
tions are subject to purifying selection (Hellmann et al.,
2003). Based on comparisons between human and
chimp, researchers have estimated that 90% of synony-
mous mutations are deleterious, albeit with weak fitness
effects (Lu and Wu, 2005). These results agree with the
weak signatures of selection detected at synonymous
sites in human population studies (Comeron, 2006). More
recent comparisons with murids suggest that approxi-
mately 20% of mutations at synonymous sites are
effectively selected against in hominids (Eory et al.,
2010; Keightley et al., 2011). It has become clear that
synonymous mutations are not entirely neutral genetic
passengers, and therefore, their phenotypic contribution
needs to be reevaluated. But what are the molecular
underpinnings of their functional importance?
Functional impact of synonymous
mutations
Evidence for functional molecular consequences of syn-
onymous mutations has been accumulating for over three
decades, with discoveries invariably prompted by the link
between synonymous mutations and various disease
phenotypes. Several detailed reviews of molecular
mechanisms involving synonymous mutations have been
published (Bali and Bebok, 2015; Cartegni et al., 2002;
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Chamary et al., 2006; Hunt et al., 2014; Parmley and Hurst,
2007; Plotkin and Kudla, 2011; Sauna and Kimchi-Sarfaty,
2011, 2013; Sauna et al., 2007; Shabalina et al., 2013),
highlighting their often overlooked importance for human
health. Mechanisms of interference with gene function
appear to be diverse, ranging from impacting mRNA
splicing to protein translation (Figure 1). Here, we provide
a brief overview of these mechanisms.
Splicing regulation is the mechanism for which the
largest set of evidence exists. The impact of mutations
(including synonymous ones) on splicing has long been
known (Cartegni et al., 2002; Krawczak et al., 1992;
Treisman et al., 1983). The mutations with the most
obvious impact are those located next to splice junctions
(Krawczak et al., 1992), and examples of such synony-
mous mutations are linked to various syndromes, includ-
ing acute intermittent porphyria (Grandchamp et al.,
1989), Tay–Sachs disease (Akli et al., 1990), phenylke-
tonuria (Chao et al., 2001), and von Hippel–Lindau dis-
ease (Martella et al., 2006). However, some of the
earliest examples of synonymous mutations linked to
aberrant splicing came from the discovery of mutations in
the b-globin gene in b-thalassemia patients. Among the
several variants found to impact the function of the
human b-globin gene, one was a synonymous substitu-
tion in codon 24 (Goldsmith et al., 1983). This substitution
activated an exonic donor splice site located in codon 25,
which led to truncation of the exon by 16 nucleotides.
This mutation is associated with a 75% decrease in
normally processed b-globin mRNA, which could be
explained by mRNA sequences being subject to non-
sense-mediated decay due to truncation-induced frame-
shift. Activation of exonic cryptic or de novo splice sites
by synonymous mutations is a well-defined molecular
mechanism that has been linked to several other syn-
dromes as well. For example, an adenine-to-guanine
transition in the growth hormone receptor gene (GHR)
activates an exonic donor splice site that results in an in-
frame deletion of 24 nucleotides from exon 6 (Berg et al.,
1992). Although the deletion does not change the reading
frame for the rest of the protein, it does eliminate eight
amino acids from the extracellular domain of GHR,
conferring resistance to growth hormone, a condition
known as Laron syndrome. Other conditions caused by
the activation of alternative splice sites include Crouzon
syndrome (Del Gatto and Breathnach, 1995; Li et al.,
1995) and Rett syndrome (Sheikh et al., 2013). We have
documented synonymous mutations with the same
effect in the CFTR gene (Scott et al., 2012).
One less obvious mechanism appeared to be in play in
the case of mutations located far from exon junctions and
which do not activate cryptic or de novo splice sites.
Instead, they cause the skipping of entire exons, as has
been reported in cases of acute intermittent porphyria
(Llewellyn et al., 1996) and Marfan syndrome (Liu et al.,
1997). The opposite phenomenon, namely excess exon
Figure 1. Conceptual representation of molecular mechanisms affected by synonymous mutations. The orange oval denotes a synonymous
mutation. (1) Interference with splicing could result in multiple outcomes, such as exon skipping, exon truncation, and retention of exons at higher
rates. Exon skipping is illustrated here as the outcome with the most obvious impact on the mature mRNA sequence. (2) Synonymous mutations
can affect the folded secondary structure of the mature transcript resulting in altered transcript stability. (3) Stability of the transcript can also be
affected by synonymous mutations through their interference with RNA-binding proteins. (4) Synonymous mutations alter the codon, which can
result in either increased or decreased translation rates depending on the relative abundance of the corresponding tRNA molecules in the cell;
ultimately, cotranslational folding may be affected, resulting in misfolded proteins. (5) Synonymous mutations can add or subtract miRNA binding
sites, leading to altered levels of expression.
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inclusion, has been observed in the case of one synony-
mous mutation in a patient suffering from dementia with
parkinsonism, wherein disruption of a splicing silencer
was suspected (D’souza et al., 1999). Other examples of
synonymous mutations disrupting exonic splicing regula-
tory sequences (i.e., splicing silencers and enhancers;
ESRs) include cases of spinal muscular atrophy (Cartegni
and Krainer, 2002), cystic fibrosis (Pagani et al., 2005),
and Treacher Collins syndrome (Macaya et al., 2009).
Historically, the functional importance of ESRs was
highlighted by the discovery of signatures of purifying
selection at synonymous sites in BRCA1 (Hurst and Pal,
2001), which were hypothesized to be due to the
presence of codon-embedded splicing regulatory ele-
ments (Orban and Olah, 2001). Subsequent larger studies
have provided further evidence in support of this hypoth-
esis (Carlini and Genut, 2006; Chamary et al., 2006;
Parmley et al., 2006), and recent figures estimate that
4% of synonymous mutations are deleterious owing to
their disruption of ESRs, with direct implications for
aberrant gene splicing (Caceres and Hurst, 2013).
The secondary structure of the transcript is another
level of regulation impacted by synonymous mutations
(Chamary and Hurst, 2005). Shen et al. (1999) have
shown that synonymous mutations in two different
genes, AARS and RPA1, lead to different folding patterns
of the processed mRNA. Similarly, synonymous muta-
tions in the human dopamine receptor D2 (DRD2) alter
the predicted folding of the transcript, leading to a
decrease in mRNA stability and translation and ultimately
to decreased dopamine-induced DRD2 expression (Duan
et al., 2003). These mutations in DRD2 are associated
with schizophrenia and alcoholism. The same study
highlights the compensatory role of some synonymous
mutations that have an indirect functional effect by
canceling the detrimental effect of other mutations.
Additional studies illustrate converging effects of syn-
onymous mutations at the level of protein through antag-
onistic effects at the level of mRNA. Specifically, reduction
in protein production could also result from increased
stability of the mRNA secondary structure. For example, a
synonymous mutation in COMT, a key regulator of pain
perception, cognitive function, and affective mood, is
associated with the most stable secondary mRNA struc-
ture, the lowest amount of translated protein, and the
lowest enzymatic activity (Nackley et al., 2006). Site-
directed mutagenesis has shown that mutations that
reduce the stability of the secondary structure result in
increases in COMT levels and enzymatic activity. How-
ever, other mechanisms that do not involve the mRNA
secondary structure, such as differential microRNA
(miRNA) targeting or interaction with ribonucleoprotein
(RNP) complexes, could also explain this result and need to
be ruled out to fully accept the hypothesis of increased
stability of mRNA secondary structure.
Another example of a mutation affecting the mRNA
secondary structure is provided by the most common
mutation associated with cystic fibrosis. This is a 3-bp
deletion in the cystic fibrosis transmembrane conduc-
tance regulator (CFTR) gene and is usually referred to as
DF508. This mutation not only eliminates residue 508, but
it leads to the replacement of the last nucleotide of codon
507 (isoleucine) by the last nucleotide of codon 508,
which is a synonymous change (codon ATC is replaced by
ATT). This change drastically alters the mRNA folding
structure, resulting in a translational pause, which conse-
quently leads to protein misfolding and degradation
(Bartoszewski et al., 2010). In bacteria, codons that
prevent secondary mRNA structures from forming are
favored at gene starts (Bentele et al., 2013; Kudla et al.,
2009). A similar effect has been observed in human as
well (Li and Qu, 2013), although it remains to be
determined whether the bias favoring certain nucleotide
variants at gene starts is due to their effect on mRNA
secondary structures.
Interaction with RNA-binding proteins can also be
influenced by synonymous mutations through affecting
protein-specific interaction sites, ultimately altering the
stability of mRNA species. Capon et al. (2004) have
shown that a synonymous mutation in corneodesmosin
(CDSN) increases mRNA stability. The synonymous
mutation decreases affinity for a 39-kDa cytoplasmic
RNA-binding protein. The effect of decreased binding is
increased stability of the CDSN transcript. The increased
stability of the transcript cannot be attributed to altered
mRNA folding, as the predicted secondary structures of
the reference and variant transcripts are virtually identical
(Figure 2). The authors conclude that this synonymous
mutation increases susceptibility to psoriasis. An antag-
onistic example, in which synonymous mutations reduce
transcript stability, is provided by synonymous mutations
that decrease the ability of SOD1 mRNA to form RNP
complexes (Ge et al., 2006). Mutations in SOD1 account
for approximately 15% of inherited mutations that cause
amyotrophic lateral sclerosis. SOD1 mRNA forms neu-
ronal tissue-specific RNP complexes, and mutations
impeding the formation of such complexes decrease
mRNA stability and, consequently, mRNA levels. How-
ever, the specific proteins that interact with the SOD1
mRNA remain to be identified.
Protein translation and folding are influenced by syn-
onymous mutations by changing the synonymous
codons. In turn, they determine the corresponding tRNA
molecules, whose abundance has been linked to trans-
lation efficiency (Bulmer, 1991; Dos Reis et al., 2004;
Gingold and Pilpel, 2011; Gustafsson et al., 2004; Stolet-
zki and Eyre-Walker, 2007; Waldman et al., 2011).
Spencer et al. (2012) have illustrated this phenomenon
in bacteria, in which a luciferase expression construct
engineered with synonymous mutations to achieve
codon optimality increases translation rates. An unex-
pected consequence of the increase in translation rate is
reduced luciferase activity. A reengineered product with
synonymous mutations that mimic the codon usage of
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Drosophila melanogaster (the closest relative to the
firefly) results in a luciferase twice as active as the wild-
type version, supporting a mechanism of protein folding
that is reliant upon ‘ribosomal rhythm’, including pauses.
These results agree with the codon optimality selection
for protein folding that has been documented in eukary-
otes (O’brien et al., 2012; Pechmann and Frydman, 2013;
Tsai et al., 2008), although the relationship between
tRNA abundance and translation speed remains con-
tentious (Charneski and Hurst, 2013; Ingolia et al., 2011).
Skewed translation rates are proposed to alter the
function of P-glycoprotein (P-gp) in human. P-gp is the
protein product of ABCB1 [the ATP-binding cassette,
subfamily B (MDR/TAP), member 1 gene], also known as
MDR1 (Kimchi-Sarfaty et al., 2007). In this case, a
synonymous mutation does not affect mRNA and protein
levels but introduces a rare codon that alters the
cotranslational folding and insertion of P-gp into the
membrane. As a result, P-gp’s interactions with drugs
and inhibitors such as cyclosporin A and verapamil are
altered. Likewise, translation efficiency influenced by
synonymous mutations has been linked to other condi-
tions, such as phenylketonuria (through a synonymous
mutation in PAH) and Best’s macular dystrophy (through
a synonymous mutation in BEST1) (Waldman et al.,
2011), as well as lack of response to Herceptin treatment
of patients with HER2-positive breast cancer (Griseri
et al., 2011).
Affinity of miRNA binding sites is also influenced by
synonymous mutations, which can change the nucleotide
sequence recognized by miRNAs. The possibility that
synonymous mutations interfere with miRNA binding
was first proposed in 2006 (Chamary et al., 2006). The
first theoretical evidence supporting this hypothesis
followed soon afterward, when Hurst (2006) showed
that gene sequences that are part of putative miRNA
pairing domains exhibit a significantly lower rate of
evolution at synonymous sites compared to the rest of
gene sequences. The case of the synonymous variant
rs10065172 in IRGM is illustrative of the dismissal of
functional relevance of synonymous variants. Although
this variant is strongly associated with Crohn’s disease in
individuals of European descent, its functional implica-
tions were disregarded as non-causative in favor of a 20-
kb deletion upstream of IRGM that occurred in perfect
disequilibrium with the synonymous variant (Mccarroll
et al., 2008). Later, an alternative hypothesis was pro-
posed for the role of this mutation, implicating interfer-
ence with posttranscriptional regulation through miRNA
binding. This hypothesis was based on computational
predictions that suggested the disruption of miR-196A
and miR-196B binding sites (Brest et al., 2011). Exper-
imental evidence showed that these miRNAs were
overexpressed in the inflammatory intestinal epithelia of
Crohn’s disease patients, resulting in the downregulation
of the IRGM variant carrying the protective C allele but
not of the variant carrying the T allele. As a result,
intracellular replication of Crohn’s disease-associated
E. coli is less effectively controlled, suggesting direct
causal involvement by the synonymous variant.
Synonymous mutations in cancer
The many examples of synonymous mutations implicated
in various human diseases, including heritable conditions
(Sauna and Kimchi-Sarfaty, 2011), suggest parallel func-
tional effects in cancers. Awareness that somatic synony-
mousmutations may include causal variants, that is, driver
mutations, is beginning to take hold. Two recent studies
provide evidence for the causal involvement of synony-
mous mutations in melanoma (Gartner et al., 2013), as
well as other cancer types (Supek et al., 2014), which
should provide added incentive to further investigate of
synonymous mutations as driver events in cancers.
A recent study of 29 melanoma exomes and genomes
revealed 16 recurrent somatic synonymous mutations
(Gartner et al., 2013). To determine the prevalence of
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Figure 2. Partial view of the secondary structure of the CDSN
transcript. The structure was predicted using mfold (http://
mfold.rna.albany.edu/?q=mfold) and 151 bps (corresponding to
coordinates chr6:31084360-31084510 in the hg19 assembly of the
human genome) centered on the position of the synonymous
mutation c.957C>T (rs1062470). The structure corresponding to the
synonymous mutation is predicted to be identical to the wild-type
structure (the mutated position is highlighted in the enlarged inset),
with the exception of the level of free energy, which is slightly lower
for the structure corresponding to the reference C allele
(DG = 46.80 kcal/mol) relative to the structure corresponding to the
synonymous T variant (DG = 44.20 kcal/mol).
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these recurrent synonymous mutations, the authors
extended the panel to include over 150 additional
melanoma samples. The study revealed two highly
recurrent mutations, one in OR4C3 and one in BCL2L12.
Both recurred at a rate greater than expected by chance,
implying that these mutations underwent selection during
tumor development. Given that BCL2L12 has previously
been implicated in tumor development, the F17F muta-
tion in BCL2L12 was further investigated in another
expanded panel of tumor samples. Of a total of 256
screened samples, 10 contained the mutation. Seque-
nom MALDI-TOF was used to determine the abundance
of transcripts for each allele using a minimum 10%
threshold of the mutant allele peak, and showed that the
variant allele was more abundantly expressed than the
wild-type allele. To test whether this increase in transcript
levels increased protein expression, the authors con-
structed both wild-type and mutated versions of BCL2L12
and transiently transfected them into a 293T cell line,
wherein the mutated version increased both transcript
and protein levels. Several miRNA target prediction
programs indicated that the change in transcript expres-
sion levels was due to differential binding of hsa-miR-671-
5p miRNA, which was predicted to bind the wild-type
BCL2L12 but not the mutant mRNA. Transfection of this
miRNA into cell lines had no effect on the mutant
BCL2L12 RNA but significantly reduced transcript levels
of the wild-type mRNA. As BCL2L12 binds TP53 and
inhibits apoptosis in glioblastoma, the authors sought to
determine its functional contribution to melanoma. Both
mutant and wild-type BCL2L12 bound TP53; however,
mutant cell lines expressing the synonymous mutation
lost the regulatory effect of hsa-miR-671-5p miRNA,
rendering them unable to properly regulate the expres-
sion of TP53-dependent target genes. The F17F mutation
in BCL2L12, which changes the phenylalanine-encoding
codon from TTC to TTT, represented an early example of
a somatic synonymous mutation with a demonstrated
functional role in cancer, confirming the predictions that
variants can lead to cancer by interfering with miRNA
binding (Ziebarth et al., 2012).
Other studies, investigating additional functional path-
ways, have started to emerge. A recent study by Supek
et al. (2014) proposed that synonymous mutations often
act as drivers in human cancers and suggested that as
many as 20–50% of synonymous mutations in oncoge-
nes are under selection. In their thorough analysis of
cancer exomes and genomes, the authors provided
statistical proof of the deleterious effects of synonymous
mutations in cancer. To search for genes enriched for
mutations, they compiled a data set containing over
200 000 missense and 100 000 synonymous mutations
generated from over 3000 exome samples comprising 11
different tissue types, with 200 samples per type. As
expected, they were able to identify genes previously
demonstrated to be enriched for missense mutations.
Unexpectedly, oncogenes carrying activating non-synony-
mous mutations also showed clear signs of enrichment
for synonymous mutations. The authors noted a 23–30%
excess of this mutation type in their cancer exome
samples when compared with a matched control gene
set. They did not observe the same enrichment in known
tumor suppressor genes, and investigation of the muta-
tional load in the UTRs of these genes indicated that local
mutation rates were not the reason for the elevated
number of synonymous mutations. Furthermore, the
authors compared the rates of synonymous mutations
in oncogenes with those in neighboring genes, as well as
simulating mutations in coding regions by sampling
mutations from introns and UTRs. Both comparisons
robustly confirmed the enrichment in synonymous muta-
tions observed in this subset of oncogenes.
To determine the predominant effect of the synony-
mous mutations, Supek et al. searched for specific biases
characteristic of the synonymous mutation set. Such
biases might be similar to those observed for missense
driver mutations, which exhibit positional biases relative
to important functional domains or amino acid positions.
To address this aspect, they assembled a collection of
383 synonymous mutations found in 18 oncogenes. Of
these, 16 exhibited high (>1.5x) enrichment for synony-
mous mutations (enrichment levels were significant for
11 of these genes). Two additional genes, ALK and
NOTCH2, exhibited slightly lower, although significant,
enrichments of 1.47x and 1.46x, respectively. These
mutations preferentially targeted evolutionarily conserved
sites and significantly clustered in known oncogenes;
these biases were not found for mutations in tumor
suppressor genes. Notably, almost a third of these
mutations (126 or 32.9%) were found in a larger set of
501 melanoma samples that we assembled by combining
data provided by TCGA with data from four other studies
(Dutton-Regester et al., 2014; Hodis et al., 2012;
Krauthammer et al., 2012; Nikolaev et al., 2012). Mela-
noma was the cancer type providing the highest fraction
of mutations, in agreement with the high mutational load
in melanomas, closely followed by lung cancers, which
contribute nearly a quarter of the mutations in this set.
Using this data set, Supek et al. noted the enrichment
of synonymous mutations near exon boundaries, hinting
at a role in exon splicing. As exonic splicing enhancers
(ESEs) and exonic splicing silencers (ESSs) are evolution-
arily conserved and relevant near exon boundaries (Keren
et al., 2010; Parmley et al., 2006; Yeo et al., 2004), they
investigated the mutations’ impact on gene splicing by
analyzing the effect of mutations on ESE and ESS
sequences. They found that synonymous mutations
preferentially created ESEs and abolished ESSs in the
considered set of oncogenes. Of the ESE gains, 43%
resulted in a gain of a known binding site for the splicing
factor SRSF1. Similarly, one cluster of mutations resulting
in ESS losses caused the loss of a known binding site for
heterogeneous nuclear ribonucleoprotein (hnRNP) H2
splicing factor. Both SRSF1 and hnRNP have previously
678 ª 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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been implicated in tumor progression, and the authors
suggest that these gains and losses could alter the
regulation of splicing and aid tumor development.
Based on the excess of synonymous mutations in
oncogenes relative to matched gene sets, Supek et al.
propose that nearly half of synonymous mutations in
oncogenes could act as driver mutations. To evaluate the
impact of synonymous mutations on gene splicing, they
have also analyzed the relation between the presence of
synonymous mutations and exon usage in the case of
samples with available RNA-Seq data. For this purpose,
they used 131 TCGA samples that have at least one
synonymous mutation in any of the 18 oncogenes
mentioned above, amounting to a total of 162 sample-
gene pairs, 52 of which include melanoma samples. The
association between synonymous mutations and exon
usage was evaluated with the Mahalanobis outlier mea-
sure, which is in effect a multivariate version of the Z
score. Of the 162 pairs, 33 (20.4%) exhibit significant
Mahalanobis outlier measure (see Figure 5A and 5E in
Supek et al., 2014), with melanoma not being signifi-
cantly different from other cancer types in this respect
(13 of 52, or 25%; P = 0.4, two-sided Fisher’s exact test).
However, the authors do not make clear whether the
predominant form of splicing alteration involves increased
exon skipping or exon retention.
To clarify this aspect, we analyzed the potential effect
of all these mutations on splicing using the program
SPANR (Xiong et al., 2015). A total of 327 mutations were
considered (56 that were not evaluated by SPANR
because they were located in terminal exons), 107 of
which are mutations occurring in melanoma. More than
half of the analyzed mutations were predicted to increase
exon skipping rates (191 of 327, or 58.4%); melanoma
was consistent with other cancer types in this respect (59
of 107, or 55.1%; P = 0.405, two-sided Fisher’s exact
test). The proportions remained roughly the same if we
limited our analysis to mutations found in the 131 TCGA
samples analyzed for differential exon usage by Supek
et al. (a total of 153 mutations, of which 47 from
melanoma), with 51.1% and 61.3% of mutations increas-
ing exon skipping rates in melanoma and other cancer
types, respectively. However, in the context of oncoge-
nes, one might expect the majority of driver mutations to
increase exon retention, and thus protein levels, which
would be consistent with activating mutations. This is
also suggested by the results of minigene splicing assays
for six mutations tested by Supek et al. (none of these
occurred in melanoma), as five of them resulted in
increased exon retention. This bias should be readily
identifiable for mutations associated with significant
differential exon usage as evaluated using RNA-Seq data
(e.g., FDR cutoff of 25% for the Mahalanobis outlier
measure), given their significant impact on gene splicing.
We found that such mutations (a total of 33; 14 occurred
in melanoma) preferentially lead to exon retention, albeit
not by a significant margin relative to mutations not
associated with a significant differential exon usage (all
mutations: 51.5% vs. 39.2%; P = 0.14, one-sided Fish-
er’s exact test; melanoma mutations: 64.3% vs. 42.4%;
P = 0.15). We observed no significant difference
between mutations associated with significant differen-
tial exon usage in melanoma and other cancer types
(64.3% vs. 42.1%; P = 0.29, two-sided Fisher’s exact
test). However, the lack of a significant bias toward exon
retention could be explained by the relatively low sample
size of mutations included in this study, but also by the
specific functions of the genes in question. For example,
the mutation most significantly associated with differen-
tial exon usage is located in a 93-bp exon of MSI2 and is
predicted to promote exon skipping (SPANR
DΨ = 1.46), not exon retention. Elimination of 31 amino
acids from MSI2 would affect one of two conserved
mRNA binding domains and thus have downstream
regulatory consequences given its important role in
posttranscriptional regulation of gene expression in a
variety of tissues (Sakakibara et al., 2001). Its oncogenic
effect is usually observed in the context of acute myeloid
leukemia when overexpressed (Kharas et al., 2010). The
alteration of one of the mRNA binding domains might be
considered a loss or reduction rather than gain of function
event, which might still be compatible with oncogenic
implications given that reduction ofMSI2 expression was
observed in higher relative to lower grade gastric carci-
nomas (Emadi-Baygi et al., 2013).
To further evaluate the potential for a driver role of the
mutations in melanoma, we quantified their frequency in
our enlarged set of 501 melanoma samples. We found
that all mutations associated with significant differential
exon usage have very low recurrence (the mutation in
MSI2 was found in two samples, whereas all the others
were found in a single sample). However, it is notable
that four of the 11 samples in which these mutations
were found also contained the most frequent BRAF non-
synonymous mutation (it is found in more than 40% of all
501 melanoma samples). The other seven samples
contained at least one high-frequency non-synonymous
mutation (i.e., found in seven or more samples). The
larger set of mutations associated with non-significant
differential exon usage also show very low frequencies,
only five of them having frequencies greater than one
(three samples was the highest observed frequency).
These observations suggest that instead of being the
main driver mutations, mutations that affect splicing in
oncogenes may facilitate tumor progression in concert
with additional mutation events, in agreement with a
model in which mutations that provide growth advantage
to the cell are acquired gradually (Fearon and Vogelstein,
1990; Nowell, 1976; Vogelstein and Kinzler, 2004; Vogel-
stein et al., 2013), in effect a generalization of the two-hit
model of tumor emergence originally detailed for
retinoblastoma (Knudson, 1971). These mutations also
raise the intriguing question of whether the impact on
splicing may in fact extend beyond a handful of
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oncogenes, and whether any relationship exists between
mutation frequency and impact on splicing.
Supek et al. observed enrichment of synonymous
mutations and their functional effects almost exclusively
in oncogenes. Nevertheless, they provided examples of
synonymous mutations affecting the tumor suppressor
gene TP53. One mutation occurred at the 30 end of exon
6, which was shown, using an in vivo assay, to cause
activation of a cryptic splice site and retention of intronic
sequence that led to shift of reading frame in the coding
sequence. Two additional recurrent synonymous muta-
tions in TP53 at the 30 ends of exons 4 and 9 showed
similar effects of directly disrupting splice junctions.
These observations highlight the relevance of splicing
defects beyond a restricted set of oncogenes.
Tools for computational prediction of
functional effects
Advances in whole-exome and whole-genome technolo-
gies have allowed us to go from a candidate gene
approach to an unbiased interrogation of the genome,
expediting interpretation of sequences in a data-driven
manner. However, the difficulty of analyzing the very high
numbers of variants revealed through modern sequenc-
ing technologies lies in properly evaluating their functional
impact. To prioritize candidates for experimental valida-
tion, the scientific community needs computational tools
to highlight the most likely causal synonymous mutations.
Although several tools are available for the specific
evaluation of non-synonymous mutations, such as SIFT
(Ng and Henikoff, 2001), PolyPhen (Adzhubei et al., 2010;
Ramensky et al., 2002), CHASM (Flanagan et al., 2010;
Wong et al., 2011), and InVEx (Hodis et al., 2012), no
tools are specifically designed to analyze synonymous
mutations. General tools can be used for this specific
case, however. For example, GERP, which measures the
evolutionary constraint of positions (Cooper et al., 2005;
Davydov et al., 2010), can be used to identify synony-
mous sites of evolutionary importance. Once variants at
those positions are identified in patient samples, they can
be tested for functional consequences.
Analysis of a mutation’s impact on gene splicing
benefits from the development of many tools aimed at
evaluating the strength of splice sites or the impact of
variants on splicing, such as MaxEntScan (Yeo and Burge,
2004), SplicePort (Dogan et al., 2007), Skippy (Woolfe
et al., 2010), Spliceman (Lim and Fairbrother, 2012),
MutPred Splice (Mort et al., 2014), and SPANR (Xiong
et al., 2015). MaxEntScan and SplicePort measure the
strength of canonical splice sites based on proximal
sequence features; the effect of specific mutations can
be interpreted by comparing the scores of splice sites
using reference and variant alleles. Spliceman and Skippy
use changes in hexamers surrounding a given variant to
predict the likelihood of splicing disruption and exon
skipping, respectively. Whereas Spliceman uses data
from 11 genomes to define splice site features, Skippy
compares the context-specific effect of a mutation to a
known set of exon skipping events. The program
MutPred Splice employs a much larger set of variants
(more than 1000) associated with disruption of splicing
(although not necessarily skipping). SPANR takes tissue-
specific function into account, predicting the change in
the fraction of transcripts with a specific exon spliced in
over a set of 16 tissues. It is important to keep in mind
that all tools have non-negligible rates of false-positive
predictions. Therefore, experimental testing should be
prioritized for cases on which multiple tools converge
with similar predictions.
Several other programs exist to analyze the effects of
synonymous mutations on RNA transcripts. Changes in
mRNA folding patterns can be predicted with mfold
(Zuker, 1989, 2003), by comparing secondary structures
predicted for reference and variant alleles. Various tools
also exist to evaluate the presence of miRNA target sites,
such as miRanda (John et al., 2004), PITA (Kertesz et al.,
2007), and TargetScan (Garcia et al., 2011). A recently
published tool, Silent Variant Analyzer (SilVA), provides a
more integrative approach by combining data on
sequence conservation, splice donor/acceptor sites,
splice factor motifs, RNA-folding energy, and codon
usage to rank synonymous variants with regard to their
functional impact (Buske et al., 2013).
Conclusion
The influence of synonymous mutations on human
disease is evident, with new examples appearing on a
regular basis. Nevertheless, very little research has been
conducted on the role of somatic synonymous mutations
in cancers, less than a handful of studies having been
published thus far. Going forward, the findings presented
here should shape the way that we analyze the abun-
dance of data being generated. Synonymous mutations
hold one of the keys to uncovering novel driver mutations
and potential novel oncogenes. The challenges of iden-
tifying causal synonymous mutations loom large, but in
silico approaches can be used to prioritize candidates
prior to any experimental undertaking. Refining the
functional relevance of synonymous mutations should
take into account the known properties of driver muta-
tions, such as their recurrence in multiple patients, their
localization at known oncogene mutational hot spots or
functional sites evolving under selective pressure. Over-
all, the evidence presented herein should help synony-
mous mutations, especially recurring events, no longer
evade the suspicion of functional importance, and effec-
tively remove the ‘silent’ label too often attached to them.
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